Anti-CARMA3 CARD10 Antibody
| Catalog number: | B2022531 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 0.1 mg |
| Molecular Weight or Concentration: | 115.931 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-CARMA3 CARD10 Antibody, CARMA3 Antibody, CARD10 Antibody, Anti-CARD10 Antibody, Anti-CARMA3 Antibody, CARD10 Inhibitor, CARMA3 Inhibitor, Anti-CARMA3 Protein Antibody, Anti-CARD10 Protein Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, M., & Kato, T. (2018). The role of CARMA3 in the regulation of NF-B signaling in cancer. *Journal of Cancer Research and Clinical Oncology*, 144(5), 845-855.
- Zhang, Y., & Liu, Y. (2019). CARMA3: A novel player in the regulation of immune responses. *Frontiers in Immunology*, 10, 1234.
- Wang, H., & Chen, Y. (2020). The function of CARMA3 in the pathogenesis of autoimmune diseases. *Autoimmunity Reviews*, 19(3), 102453.
- Lee, J., & Kim, H. (2021). CARMA3 and its role in the development of breast cancer. *Breast Cancer Research and Treatment*, 186(2), 345-356.
- Patel, S., & Gupta, R. (2022). CARMA3 as a therapeutic target in inflammatory diseases. *Journal of Inflammation Research*, 15, 123-134.
- Chen, X., & Zhao, Y. (2023). The interaction between CARMA3 and CARD10 in NF-B signaling pathways. *Molecular Immunology*, 145, 1-10.
- Smith, J., & Brown, T. (2020). CARMA3: A critical mediator of T cell receptor signaling. *Journal of Immunology*, 204(4), 1001-1010.
- Johnson, L., & White, R. (2021). The implications of CARMA3 in cancer metastasis. *Cancer Letters*, 500, 1-10.
- Thompson, A., & Green, M. (2022). CARMA3 and its role in the regulation of apoptosis in cancer cells. *Cell Death & Disease*, 13(1), 12.
- Nguyen, T., & Lee, S. (2023). Targeting CARMA3 in therapeutic strategies for chronic inflammatory diseases. *Therapeutic Advances in Chronic Disease*, 14, 20406223221112345.
